𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Curupira tefeensis (Olacaceae) — A Rich Source of Very Long Chain Fatty Acids

✍ Scribed by Spitzer, V. ;Marx, F. ;Maia, J. G. S. ;Pfeilsticker, K.

Publisher
John Wiley and Sons
Year
1990
Weight
372 KB
Volume
92
Category
Article
ISSN
0931-5985

No coin nor oath required. For personal study only.

✦ Synopsis

M a r x , J. G. S. M a i a andK. P f e i l s t i c k e r * *

The fatty acid composition of the seed oil of Curupira tejiemis was analysed by capillary GC of their methyl esters. The gaschromatographic assignments were ensured by corresponding mass spectra. The oil is composed to more than 62 O/n of very long chain fatty acids (> C18). Erucic acid is found to be the main component (35%). The position of the double bonds of the rnonounsaturated fatty acids (MUFAME) was verified after derivatization with dimethyl disulfide and subsequent GUMS analysis. AU identified MUFAME belong to the (n-%)type. The UV-spectroscopical data show that approx. 1.2% conjugated acetylenic fatty acids occur in the oil. Furthermore IKand NMRspectroscopical investigations and the basic analyses of the seed were carried out.

📜 SIMILAR VOLUMES

Issues surrounding fish as a source of o
Issues surrounding fish as a source of omega-3 long-chain polyunsaturated fatty acids
✍ Douglas Tocher 📂 Article 📅 2009 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 381 KB

## Abstract Fish are a virtually unique, rich source of omega‐3 long‐chain polyunsaturated fatty acids (ω3 LC‐PUFA) in the human diet. This article describes the origins of ω3 LC‐PUFA in fish and the increasingly important role of aquaculture in the provision of fish for human consumption. It also

How good is the evidence for a favourabl
How good is the evidence for a favourable effect of very long chain n-3 polyunsaturated fatty acids on cardiovascular disease?
✍ John Stanley 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 411 KB

## Abstract The evidence for beneficial effects of very long chain (VLC) n‐3 polyunsaturated fatty acids (PUFA) on cardiovascular disease (CVD) is strong because it is based on the results of adequately powered intervention trials with disease endpoints. This contrasts with the evidence for a detri